Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Finn

Showing results (461-470 of 527) with videos related to

Pageof 53
Sort By:
Lancet (London, England)|April 19, 2023
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.
Hepatology (Baltimore, Md.)|July 5, 2014
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trialMasatoshi Kudo, Guohong Han, Richard S Finn, et al.
Cancer|November 24, 2020
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240Baek-Yeol Ryoo, Philippe Merle, Amit S Kulkarni, et al.
The Lancet. Oncology|June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialAndrew X Zhu, Richard S Finn, Julien Edeline, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2019
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialRichard S Finn, Baek-Yeol Ryoo, Philippe Merle, et al.
Nature Medicine|June 23, 2022
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinomaAndrew X Zhu, Alexander R Abbas, Marina Ruiz de Galarreta, et al.
Nature Medicine|February 20, 2024
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trialHyung-Don Kim, Seyoung Jung, Ho Yeong Lim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 26, 2021
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiologyPeter R Galle, Masatoshi Kudo, Josep M Llovet, et al.
NPJ Precision Oncology|August 16, 2022
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclibZhou Zhu, Nicholas C Turner, Sherene Loi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancerGottfried E Konecny, Boris Winterhoff, Teodora Kolarova, et al.
Pageof 53

Showing results (461-470 of 527) with videos related to

Sort By:
Pageof 53
Lancet (London, England)|April 19, 2023
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.
Hepatology (Baltimore, Md.)|July 5, 2014
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trialMasatoshi Kudo, Guohong Han, Richard S Finn, et al.
Cancer|November 24, 2020
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240Baek-Yeol Ryoo, Philippe Merle, Amit S Kulkarni, et al.
The Lancet. Oncology|June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialAndrew X Zhu, Richard S Finn, Julien Edeline, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2019
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialRichard S Finn, Baek-Yeol Ryoo, Philippe Merle, et al.
Nature Medicine|June 23, 2022
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinomaAndrew X Zhu, Alexander R Abbas, Marina Ruiz de Galarreta, et al.
Nature Medicine|February 20, 2024
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trialHyung-Don Kim, Seyoung Jung, Ho Yeong Lim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 26, 2021
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiologyPeter R Galle, Masatoshi Kudo, Josep M Llovet, et al.
NPJ Precision Oncology|August 16, 2022
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclibZhou Zhu, Nicholas C Turner, Sherene Loi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancerGottfried E Konecny, Boris Winterhoff, Teodora Kolarova, et al.
Pageof 53